James O Lindsay, Daniel Hind, Lizzie Swaby, Hannah Berntsson, Mike Bradburn, Uday Bannur C, Jennifer Byrne, Christopher Clarke, Lauren Desoysa, Ben Dickins, Shahida Din, Richard Emsley, Gemma A Foulds, John Gribben, Christopher Hawkey, Peter M Irving, Majid Kazmi, Ellen Lee, Amanda Loban, Alan Lobo, Yashwant Mahida, Gordon W Moran, Diana Papaioannou, Miles Parkes, Andrew Peniket, A Graham Pockley, Jack Satsangi, Sreedhar Subramanian, Simon Travis, Emily Turton, Ben Uttenthal, Sergio Rutella, John A Snowden
BACKGROUND: A previous controlled trial of autologous haematopoietic stem-cell transplantation (HSCT) in patients with refractory Crohn's disease did not meet its primary endpoint and reported high toxicity. We aimed to assess the safety and efficacy of HSCT with an immune-ablative regimen of reduced intensity versus standard of care in this patient population. METHODS: This open-label, multicentre, randomised controlled trial was conducted in nine National Health Service hospital trusts across the UK...
February 7, 2024: Lancet. Gastroenterology & Hepatology